Facial vasculitic rash associated with intravenous immunoglobulin.
Howse
M
M
South Tees Acute Hospitals Trust, Middlesbrough TS4 3BW.
Bindoff
L
L
Carmichael
A
A
D000287:Administration, Topical; D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017332:Cetirizine / Q000627:therapeutic use; D002990:Clobetasol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005148:Facial Dermatoses / Q000139:chemically induced*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000209:etiology*
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; C010893:clobetasone butyrate; D002990:Clobetasol; D017332:Cetirizine